Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM11A-31-BHS in Mild to Moderate Alzheimer's Disease
NCT03069014Phase 2Completed
- Sponsor
- PharmatrophiX, Inc.
- Start
- Feb 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of LM11A-31 in Alzheimer's disease (AD), sponsored by PharmatrophiX, Inc.. Started Feb 2017; status: completed.
02
Drugs
LM11A-31
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03069014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069014.